Fas single nucleotide polymorphisms and risk of thyroid and salivary gland carcinomas: A case-control analysis

Head and Neck

Volumn 30, Issue 3, 2008, Pages 297-305

  Ho, Tang ^a,b   Li, Guojun ^a   Zhao, Chong ^a   Zheng, Rong ^c   Wei, Qingyi ^a   Sturgis, Erich M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CANCER HOSPITAL   (China)

Author keywords

Case control studies; Fas; Humans; Salivary gland carcinomas; Thyroid carcinomas

Indexed keywords

FAS ANTIGEN;

ADULT; ARTICLE; BENIGN TUMOR; CANCER RISK; CASE CONTROL STUDY; CONTROL GROUP; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SALIVARY GLAND CARCINOMA; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; THYROID CARCINOMA;

ANTIGENS, CD95; CARCINOMA; CASE-CONTROL STUDIES; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); SALIVARY GLAND DISEASES; SALIVARY GLAND NEOPLASMS; THYROID DISEASES; THYROID NEOPLASMS;

EID: 41649095381     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20699     Document Type: Article

References (30)

1. Nagataki S, Nystrom E. Epidemiology and primary prevention of thyroid cancer. Thyroid 2002;12:889-896.
2. Modan B, Chetrit A, Alfandary E, et al. Increased risk of salivary gland tumors after low-dose irradiation. Laryngoscope 1998;108:1095-1097.
3. Zheng R, Wang LE, Bondy ML, Wei Q, Sturgis EM. γ Radiation sensitivity and risk of malignant and benign salivary gland tumors: a pilot case-control analysis. Cancer 2004;100:561-567.
4. Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69:415-429.
5. Giordano C, Stassi G, De Maria R, et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 1997;275:960-963.
6. Mitsiades N, Poulaki V, Kotoula V, et al. Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto's thyroiditis. J Clin Endocrinol Metab 1998;83:2199-2203.
7. Gannot G, Bermudez D, Lillibridge D, Fox PC. Fas and Fas-mediated effects on a human salivary cell line in vitro: a model for immune-mediated exocrine damage in Sjogren's syndrome. Cell Death Differ 1998;5:743-750.
8. Muschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000;78: 312-325.
9. Zheng R, Dahlstrom KR, Wei Q, Sturgis EM. γ Radiation-induced apoptosis, G2 delay, and the risk of salivary and thyroid carcinomas-a preliminary report. Head Neck 2004;26:612-618.
10. NIEHS-SNPs. Environmental genome project, NIEHS ES15478. Seattle, WA: Department of Genome Sciences 2007.
11. Huang QR, Manolios N. Investigation of the -1377 polymorphism on the Apo-1/Fas promoter in systemic lupus erythematosus patients using allele-specific amplification. Pathology 2000;32:126-130.
12. Stram DO, Leigh Pearce C, Bretsky P, et al. Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a case-control study of unrelated individuals. Hum Hered 2003;55:179-190.
13. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-989.
14. Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-1169.
15. Bel Hadj Jrad B, Mahfouth W, Bouaouina N, et al. A polymorphism in FAS gene promoter associated with increased risk of nasopharyngeal carcinoma and correlated with anti-nuclear autoantibodies induction. Cancer Lett 2006;233:21-27.
16. Wang LE, Cheng L, Spitz MR, Wei Q. Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer 2003;42:1-8.
17. Lai HC, Sytwu HK, Sun CA, et al. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 2003;103:221-225.
18. Ueda M, Terai Y, Kanda K, et al. Fas gene promoter - 670 polymorphism in gynecological cancer. Int J Gynecol Cancer 2006;16 (Suppl 1):179-182.
19. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004;96:1030-1036.
20. Sibley K, Rollinson S, Allan JM, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003;63: 4327-4330.
21. Krippl P, Langsenlehner U, Renner W, Koppel H, Samonigg H. Re: polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 96:1478-1479; author reply 1479.
22. Nelson HH, Kelsey KT, Bronson MH, Mott LA, Karagas MR. Fas/APO-1 promoter polymorphism is not associated with non-melanoma skin cancer. Cancer Epidemiol Biomarkers Prev 2001;10:809-810.
23. Li C, Wu W, Liu J, et al. Functioned polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenet Genomics 2006;16:245-251.
24. Engelmark MT, Renkema KY, Gyllensten UB. No evidence of the involvement of the Fas -670 promoter polymorphism in cervical cancer in situ. Int J Cancer 2004;112:1084-1085.
25. Zhang X, Miao X, Sun T, et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005;42:479-484.
26. Basolo F, Giannini R, Faviana P, et al. Thyroid papillary carcinoma: preliminary evidence for a germ-line single nucleotide polymorphism in the Fas gene. J Endocrinol 2004;182:479-484.
27. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577-582.
28. Abu-Helu RF, Dimitriou ID, Kapsogeorgou EK, Moutsopoulos HM, Manoussakis MN. Induction of salivary gland epithelial cell injury in Sjogren's syndrome: in vitro assessment of T cell-derived cytokines and Fas protein expression. J Autoimmun 2001;17:141-153.
29. Chosa N, Kyakumoto S, Kito N, Kamo M, Sato N. Mechanism of Fas-mediated cell death and its enhancement by TNF-α in human salivary gland adenocarcinoma cell line HSG. Eur J Oral Sci 2004;112:338-346.
30. Niemela JE, Hsu AP, Fleisher TA, Puck JM. Single nucleotide polymorphisms in the apoptosis receptor gene TNFRSF6. Mol Cell Probes 2006;20:21-26.